Pharma Blog Watch

Schering-Plough's PEG-Intron Approved in China (Pharma Gazette)
In her blog, Gloria Gamat reports that Schering-Plough's PEG-Intron has been approved by regulatory authorities in China for treating chronic hepatitis B. The drug "is the only pegylated interferon indicated in China for a 24-week treatment duration in the hepatitis B patient population."

"The Chinese regulatory approval followed positive clinical data of a multicenter trial in e-antigen-positive chronic hepatitis B patients in China."